Characteristics | Cases | RFC4 expression | Pvalue | |
---|---|---|---|---|
Normal expression | Overexpression | |||
Sex | Â | Â | Â | 0.059 |
Female | 147 | 59 (40.1%) | 88 (59.9%) | Â |
Male | 184 | 93 (45.9%) | 91 (54.1%) | Â |
Age | Â | Â | Â | 0.301 |
≤60 | 167 | 72 (43.1%) | 95 (56.9%) |  |
>60 | 164 | 80 (48.8%) | 84 (51.2%) | Â |
Tumor location | Â | Â | Â | 0.344 |
Colon | 154 | 75 (48.7%) | 79 (51.3%) | Â |
Rectal | 177 | 77 (43.5%) | 100 (56.5%) | Â |
Differentiation | Â | Â | Â | 0.004 |
Well/Moderate | 299 | 145 (48.5%) | 154 (51.5%) | Â |
Poorly | 32 | 7 (21.9%) | 25 (78.1%) | Â |
Preoperative CEA level | Â | Â | Â | 0.656 |
< 5 ng/ml | 194 | 89 (45.9%) | 105 (54.1%) | Â |
≥ 5 ng/ml | 111 | 48 (43.2%) | 63 (56.8%) |  |
Preoperative CA19-9 level | Â | Â | Â | 0.560 |
< 37 U/ml | 238 | 109 (45.8%) | 129 (54.2%) | Â |
≥37 U/ml | 67 | 28 (41.8%) | 39 (58.2%) |  |
pT (invasion depth) | Â | Â | Â | 0.479 |
T1 | 6 | 1 (16.7%) | 5 (83.3%) | Â |
T2 | 54 | 27 (50.0%) | 27 (50.0%) | Â |
T3 | 233 | 106 (45.5%) | 127 (54.5%) | Â |
T4 | 38 | 18 (47.4%) | 20 (52.6%) | Â |
pN (lymph node metastasis) | Â | Â | Â | 0.055 |
N0 | 197 | 99 (49.2%) | 98 (50.8%) | Â |
N1-2 | 134 | 53 (46.3%) | 81 (53.7%) | Â |
pM (distant metastasis) | Â | Â | Â | 0.795 |
M0 | 299 | 138 (46.2%) | 161 (53.8%) | Â |
M1 | 32 | 14 (43.8%) | 18 (56.2%) | Â |
TNM stage | Â | Â | Â | 0.036 |
I + II | 193 | 98 (50.8%) | 95 (49.2%) | Â |
III + IV | 138 | 54 (39.1%) | 84 (60.9%) | Â |